OPM Reports Positive Phase 1 Results for OPM-101 in Healthy Volunteers

OPM-101 Shows Promise in Phase 1 Trial

Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign Group, has announced positive results from its Phase 1 clinical trial of OPM-101 in healthy volunteers 1

1

. The study, which marks a significant milestone for the company, demonstrated strong target engagement and an excellent safety profile for the drug candidate.

Study Design and Outcomes

The Phase 1 trial was a randomized, double-blind, placebo-controlled study conducted in a single center in France. It involved 64 healthy male volunteers and evaluated single ascending doses of OPM-101 2

2

. The primary objectives of the study were to assess the safety, tolerability, and pharmacokinetics of OPM-101.

Key findings from the trial include:

1. Excellent safety profile with no serious adverse events reported
2. Strong target engagement observed
3. Favorable pharmacokinetic profile suitable for once-daily oral dosing

Implications for Neurodegenerative Disease Treatment

OPM-101 is a potent, brain-penetrant, and selective LRRK2 inhibitor. LRRK2 (Leucine-rich repeat kinase 2) is a protein kinase that has been implicated in the pathogenesis of Parkinson's disease and other neurodegenerative disorders 1

1

. The positive results from this Phase 1 trial suggest that OPM-101 could potentially be an effective treatment for these conditions.

Next Steps in Development

Following these encouraging results, OPM plans to initiate a Multiple Ascending Dose (MAD) study in the first half of 2024 2

2

. This study will further evaluate the safety and efficacy of OPM-101 and provide additional data to support its continued development.

Company Perspective

Dr. Philippe Genne, Chairman and CEO of OPM, expressed enthusiasm about the results, stating, "We are very pleased with these initial clinical results for OPM-101, which demonstrate its potential as a best-in-class LRRK2 inhibitor for the treatment of Parkinson's disease" 1

1

. He further emphasized the company's commitment to advancing treatments for neurodegenerative diseases.

Market Impact

The positive Phase 1 results have significant implications for OPM's position in the competitive landscape of neurodegenerative disease treatments. As the company progresses with the development of OPM-101, it may attract increased attention from investors and potential partners in the pharmaceutical industry.